No abstract

No abstract

No abstract

1425 pg/mL [2370], p=0.002), and more atrial fibrillation (54% v 29%, p=0.03) compared to HFpEF without RVD. BMI remained inversely associated with HFpEF-RVD after adjustment for age, sex, and race (p=0.02). HFpEF-RVD trended towards increased all-cause 30-D hospital readmission (34.8% v 19%, p=0.12) and worse survival at 1 year (70% v 87.5%, p=0.06). DA had no significant effect on urine output, weight change, or renal function in HFpEF-RVD; however, DA was associated with shorter hospital length of stay (LOS) in HFpEF-RVD in testing for interaction effects between RVD and DA (p=0.01, Figure ). Conclusion: HFpEF-RVD reflects a sicker subgroup of HFpEF patients. Amongst hospitalized HFpEF, low-dose dopamine was associated with shorter LOS in HFpEF-RVD. Future studies should be performed to find useful therapies in this subgroup of HFpEF.

No abstract